Abstract
Diabetic kidney disease (DKD) is the major reason of chronic kidney disease (CKD)-caused end-stage renal failure (ESRF), and leads to high mortality worldwide. At present, the treatment of DKD is mainly focused on controlling the hyperglycemia, proteinuria, and hypertension, but is insufficient on the effective delay of DKD progression. Cordyceps sinensis is a kind of wild-used precious Chinese herb. Its extracts have effects of nephroprotection, hepatoprotection, neuroprotection, and protection against ischemia/reperfusion-induced injury, as well as anti-inflammatory and anti-oxidant activities. According to the theory of traditional Chinese medicine, Cordyceps sinensis can tonify the lung and the kidney. Several Chinese patent medicines produced from Cordyceps sinensis are often used to treat DKD and achieved considerable efficacy. This review summarized the clinical usage of Cordyceps sinensis, as well as its mainly biological activities including anti-hyperglycemic, anti-inflammatory, immunomodulatory, anti-oxidant, anti-fibrotic activities and regulation of apoptosis.
Introduction
The prevalence of chronic kidney disease (CKD) is gradually increasing worldwide. If not treated timely, CKD may lead to heavy economic burden and poor prognosis by turning into end-stage renal failure (ESRF), which has no alternative treatment but renal replacement (). Diabetic kidney disease (DKD) has become the major reason of CKD-caused ESRF. DKD occurs in approximately 30% of patients with type 1 diabetes mellitus (T1DM) and 40% of patients with type 2 diabetes mellitus (T2DM), and about 50% of cases are in developed countries (; ). Moreover, DKD is often associated with cardiovascular disease and causes high mortality. Therefore, early diagnosis and treatment of DKD are highly essential. Several medicines are demonstrated to mitigate the progress of DKD via reducing the proteinuria, such as the renin-angiotensin system (RAS) antagonists, sodium glucose co-transporter 2 (SGLT-2) inhibitors, the glucagon like peptide-1 (GLP-1) receptor agonists (; ; ; ). However, applications of these agents can be limited by their adverse effects. For example, RAS antagonists may raise the risk of hyperkalemia and hypotension, and SGLT2 inhibitors might result in mycotic genital infections, diabetic ketoacidosis, and acute kidney injury in patients who have volume depletion or borderline arterial pressure (; ).
Increasing studies have been conducted on the pathogenesis of DKD over the past years, and it has been demonstrated that inflammation, oxidative stress, apoptosis, and fibrosis play vital role in the pathogenesis of DKD (; ; ). Applications of traditional Chinese medicine (TCM) in the treatment of DKD have become hot topics because of its advantage of muti-target therapy, which can reduce the side effects caused by other agents and increases efficacy. Based on it, TCM is used as an adjunctive treatment for DKD, improving the symptoms in patients with DKD, and alleviating the inflammation, oxidative stress, renal fibrosis, and so on (; ).
Cordyceps sinensis (BerK.) Sacc (Figure 1), also called Cordyceps sinensis (C. sinensis), is a kind of ascomycetes parasitic fungi which belongs to family clavicipitaceae, and it is mainly parasitic on insects and other arthropods (). In China, C. sinensis is a precious Chinese herb with a medical history of hundreds of years. C. sinensis is first mentioned from Ben Cao Bei Yao (written by Wang Ang, tracing back to 1694AD). C. sinensis is wildly used in clinic, especially for nourishing the kidney and tonifying the lung. Furthermore, several medicinal preparations produced from C. sinensis are extensively used as auxiliary agents for the clinical treatment of DKD (; ). Nowadays, increasing researches have identified the bioactive ingredients in C. sinensis which can induce various effects on the treatment of DKD, such as anti-hyperglycemia, anti-inflammatory, anti-oxidant activities (; ; ; ). There are many mechanisms supporting the role of C. sinensis for the treatment of DKD. Therefore, keeping in view of the above facts, this review summarizes the recent studies pertaining to the chemical constituents, pharmacology, and toxicity of C. sinensis, and the biological activities of C. sinensis in DKD treatment to provide evidence for better clinical use of C. sinensis.
FIGURE 1
2 Toxicity, Chemical Constituents, and Pharmacology
The genus of cordyceps is abundant. More than 400 species of cordyceps distributed widely, mainly in North America, Europe, East and Southeast Asia. At present, some studies have demonstrated that C. sinensis has a variety of pharmacological effects, such as nephroprotective, hepatoprotective, neuroprotective, anti-inflammatory, and anti-oxidant activities (; ). Due to the harsh environment in which it grows, C. sinensis is rare and precious, so it is important to explore its main active ingredients for better utilization.
2.1 The Safety and Toxicity of Cordyceps sinensis
C. sinensis is widely used as the medicinal plant and health food. For the moment, there is still debate about whether we should worry about the toxicity of C. sinensis. The most prominent concern is about the accumulation of heavy metals, especially arsenic (As) in C. sinensis due to the impact of global environmental pollution. In 2016, it was warned by the National Medical Products Administration (NMPA) that long-term use of C. sinensis may lead to health risks, based on that total As in C. sinensis and its related products is 4.4–9.9 mg/kg (). However, As in C. sinensis is hard to be absorbed by human body (). Besides, limited intake of C. sinensis cannot cause significant harm to human body (). Generally, the recommended dose of C. sinensis should not exceed 4 g per day and should not be used for more than 5 months per year (). Based on the existing studies, a clinical use of C. sinensis 3–6 g/day in patients with chronic renal failure was safe and could slow the progression of renal function (). Allen et al. found that daily taken 3.15 g of the synthetic compound of C. sinensis for 5 weeks had no additional adverse reactions compared with placebo (). Moreover, cultured C. sinensis has higher controllability on their growth environment, so it has certain advantages over natural C. sinensis in the control of heavy metal content, and Li et al. used the xanthine oxidase assay, the induction of hemolysis assay and the lipid peroxidation assay to confirm the strong anti-oxidant activity of both natural C. sinensis and cultured Cordyceps mycelia (), suggesting that natural C. sinensis can be replaced by cultured C. sinensis (). So, C. sinensis is considered to be safe. In brief, the toxicity of C. sinensis is controllable by rational intake and replacement by cultured ones.
The Main Chemical Constituents and Pharmacology of Cordyceps sinensis
A variety of C. sinensis derivatives have been applied to the clinic. The strains isolated from C. sinensis have been artificially cultivated and fermented into various products are in clinical use in China (). There are 9 kinds of productions, among them, Jinshuibao capsule, Bailing capsule, and Zhiling capsule are wildly used to ameliorate the kidney function in patients with chronic renal failure, renal transplant and DKD (; ; ; ). Many active components have been identified from C. sinensis, including cordycepin, adenosine, sterols, and many polysaccharides (; ; ). The main biological effects of those active components are concluded in Table1. Cordycepin (3′-deoxyadenosine) is considered as the most representative bioactive constituents and the marker of the quality of C. sinensis (). Cordycepin is a nucleoside analogue composed of a purine molecule linked to a ribose sugar, with a content ranged from 0.0076% to 0.029% (w/w) in C. sinensis (). Cordycepin is involved in the process of transcription and activation of polymerases, exerting the anti-hyperglycemia, anti-inflammatory, and immunomodulatory effects via interfering in mTOR signal pathway, then repressing apoptosis and alleviating the kidney injury in DKD (; ; ).
TABLE 1
| Classification | Constituent | Therapeutic Effect | Reference |
|---|---|---|---|
| Nucleosides | Cordycepin | Ant-itumor, anti-inflammatory, anti-microbial, anti-hyperglycemia, inhibition of platelet aggregation, hypolipidemic, analgesic, immunomodulatory, antileukemic, neuroprotective activities | |
| Adenosine | Anti-convulsant, anti-inflammatory, inhibition of neurotransmitter release, modulation of adenylate cyclase, immunomodulatory, cardioprotection activities | ||
| Guanosine | Immunomodulatory effect | ||
| Cordysinin A-E | Cerebroprotective, superoxide anion inhibition, anti-inflammatory effects | ||
| Polysaccharides | Exopolysaccharide fraction (EPSF) | Anti-tumor, anti-oxidant, anti-inflammatory, Immunomodulatory activities | |
| Acid polysaccharide (APS) | Anti-oxidant, Immunomodulatory effects | ||
| CPS-1 | Anti-oxidant, anti-inflammatory, immunomodulatory, metabolic regulation, nephroprotective, anti-hyperglycemia activities | ||
| CPS-2 | Cell proliferation inhibition, protection of chronic renal failure | ||
| Mannoglucan | Anti-tumor, cytotoxicity activity | ||
| CME-1 | Anti-oxidant activity, platelet activation | ||
| PS-A | Inhibitory activity against cholesterol esterase | ||
| Cordyglucan | Anti-tumor, immunomodulatory activities | ||
| D-mannitol (Cordycepic acid) | Anti-inflammatory, anti-fibrosis, diuretic, improve the plasma osmotic pressure, anti-free radical, anti-tussive activities | ||
| Sterols | Ergosterol | Anti-tumor, cytotoxicity, antimicrobial activities | |
| H1-A | Inhibit mesangial proliferation, regulation of apoptosis, immunomodulatory, reduce the production of anti-dsDNA | ||
| β-sitosterol | Anti-tumor, anti-hyperglycemia, hypolipidemic, anti-arthritic, hepatoprotective activities | ||
| Cerevisterol | Anti-inflammatory, anti-oxidant, anti-microbial, anti-hypoxia activities | ||
| 5α,8α-epidioxy-24(R)-methylcholesta-6,22-dien-3β-D-glucopyranoside and 5α,6α-epoxy-24(R)-methylcholesta-7,22-dien-3β-ol | Anti-tumor | ||
| Amino acids and Polypeptides | Cordymin | Anti-inflammatory, anti-nociceptive, using for diabetic osteopenia | |
| Cyclodipeptides A | Anti-malarial, cytotoxic activities | ||
| Cordycemides A and B | cytotoxic activity |
The main active extracts in Cordyceps Sinensis.
Adenosine is another main bioactive constituents of C. sinensis. The best-known effects of adenosine are anti-inflammatory and anti-convulsant activities (). Adenosine exerts biological effects and signal transduction via binding to adenosine receptors distributed on cell membranes, which are widely expressed in metabolic regulatory organs and kidney (). Adenosine plays a critical role in regulating glomerular perfusion pressure, filtration rate and renal tubular reabsorption, as well as influencing insulin secretion and regulating glucose homeostasis (). Modulating adenosine receptor signal transduction is a new strategy for the treatment of DKD. Adenosine contributes to protecting DKD-related renal insufficiency by reducing the production of pro-inflammatory cytokines (e.g. TNF-α, IL-12, INF-γ) and increasing the expression of anti-inflammatory cytokines, such as IL-10 (). Although there is still ongoing research about its anti-oxidant activities. Previous study have shown that adenosine could prevent oxidative stress damage to cells by inducing an increase of glutathione peroxidase 1 ().
Polysaccharides are important and complex active components of C. sinensis, and the different types of polysaccharides separated from C. sinensis also have the activities of anti-inflammatory, anti-oxidant, metabolic regulation and so on (; ). CPS-1, a polysaccharide constituent detected in C. sinensis, is reported to has an insulin-like effect and promote the secretion of insulin, and it is expected to be developed as an agent to anti-diabetes (). Besides, various polysaccharides (such as EPS, CPS-F) exert anti-inflammatory and anti-oxidant activities via inhibiting the expression of pro-inflammatory cytokines, promoting the secretion of anti-inflammatory cytokines and scavenging free radicals to slow the progression of DKD (; ). In addition to focusing on a single component, it is also deemed that the effect of C. sinensis comes from a combination of various components. The anti-oxidant activity of C. sinensis may be related to the combined effects of polysaccharides, flavonoids, and polyphenols (also called the hydrogen-donating anti-oxidants) (; ). In order to clarify the mechanism of C. sinensis, further exploration is needed in the future.
3 The Biological Activities of Cordyceps sinensis in Treating Diabetic Kidney Disease
Persistent hyperglycemic environment enhances the protein glycation reaction, and increase of advanced glycation end products (AGEs), which can stimulate the production of reactive oxygen species (ROS) (). Accumulated ROS induces oxidative stress and inflammation, meanwhile activates various signaling pathway, such as mitogen-actived protein kinases (MAPKs) and nuclear factor-κB (NF-κB) pathway, which in turn aggravated oxidative stress and inflammation (; , , ). Besides, excessive ROS could attack the unsaturated fatty acids in the biofilm phospholipid bilayer, causing lipid peroxidation and insulin resistance and then triggering multiple cascading reactions (). The role of the signal mechanism in the treatment of DKD by C. sinensis will be discussed separately below.
3.1 Anti-Hyperglycemic Activity
The most important target for DKD treatment is to control hyperglycemia as early as possible. Long-term hyperglycemia is considered to be the main reason for abnormalities of tissue and microvascular. The role of C. sinensis in the treatment of DKD has been demonstrated (). Jinshuibao capsule, a kind of cordyceps preparation, had additional beneficial effects on the DKD patients treated with angiotensin receptor blockers (ARB), and ameliorating the outcomes of patients (). Several active constituents contribute to the anti-hyperglycemic activity. High fiber in the fruiting body of C. sinensis could improve glucose intake and insulin resistance of cells, which might due to its influence on glucose absorption (). Moreover, polysaccharides are also the pivotal active constituents in anti-hyperglycemia. Polysaccharides-enriched extract could lower glycemic levels by 60–70% (). CS-F10, a polysaccharide derived from C. sinensis hot water extracts, significantly reduced the glucose levels both in normal and hyperglycemic mice by increasing the activity of glucokinase in livers ().
Besides, metabolic factors such as insulin levels and resistances may also be the central factors in DKD (). Insulin resistance can act on the glomeruli by mediating metabolism and hemodynamics, resulting in intraglomerular hypertension and thus influencing the progression of DKD (). Moreover, insulin resistance can also lead to the high salt-sensitivity, which associates with albuminuria and impairment of renal function, increasing the risk of macrovascular dysfunction (). Therefore, boosting insulin sensibility is imperative. It was shown that both the fermentation mycelia and the fermentation liquid of C. sinensis could significantly improve glucose response in OGTT and boost the insulin level in nicotinamide and streptozotocin (STZ)-induced diabetic rats (). Several studies demonstrated that polysaccharides in C. sinensis could significantly decrease the blood glucose, and increase the insulin sensitivity in diabetic models (; ). In the state of insulin resistance, the impairment of insulin signaling in mesangial cells (MCs) might cause hypertrophy, proliferation, and matrix deposition of MCs (). Normally, relying on the actin cytoskeleton of podocytes, the glucose transporter 4 (GLUT4)-rich vesicles can be translocated, which helps the insulin-induced glucose uptake, while the destruction of insulin signaling leads to damage of the actin cytoskeleton, and the GLUT4 nuclear translocalization function is missing, eventually contributing to the loss of podocytes and the production of proteinuria (; ). β-sitosterol, an effective anti-oxidant and anti-hyperlipidemia plant sterol in C. sinensis, was reported to lower lipid levels, restore insulin sensitivity, and activate insulin receptors and GLUT4 in adipose tissue and eventually exert anti-hyperglycemia activity in diabetic rats (). Cordycepin also plays a vital role in attenuating insulin resistance. It could improve insulin sensitivity by monitoring serum insulin levels and homeostasis model assessment of the insulin resistance index ().
In addition, pathogenic oxygen free radicals caused by hyperglycemia play an important role in the pathogenesis of DKD (). CSP-1, a polysaccharide which was separated from C. sinensis, had the effects of scavenging free radicals, and exerted anti-hyperglycemia effect via significantly decreasing the level of glucose by inducing the release of insulin in the remainder pancreatic cells and/or reducing the insulin metabolism (). The metabolic process of glucose involves varieties of reactions and participations of cytokines. Among them, as an important endocrine organ, adipose tissue is closely related to inflammation and insulin resistance by secreting various hormones, pro- and anti-inflammatory adipokines, which can affect glucose, lipid metabolism and energy homeostasis (). Patients with T2DM have more visceral subcutaneous fat than normal individuals, hyperglycemia causes macrophages in adipose tissue to secrete pro-inflammatory factors, and stimulates the accumulation of ectopic fat, so that the secretion of pro- and anti-inflammatory adipocytokines is imbalanced (). The increase of pro-inflammatory adipocytokines, such as leptin, can aggravate inflammation via stimulating the secretion of inflammatory factors (TNF-α, IL-6, IL-12), and the increase of resistin reduces the anti-inflammatory effect of adiponectin, meantime inducing the aggravation of insulin resistance (). Using C. sinensis could significantly improve the insulin sensitivity and boost the expression of adiponectin within plasma and adipose tissue in STZ-induced diabetic mice (). Thus, C. sinensis might become an effective adjuvant medicine in the treatment of DKD by its anti-hyperglycemic function and improving insulin resistance.
3.2 Anti-Inflammatory Activity
Chronic low-grade inflammation, also known as metaflammation, is a factor associated with the initiation and development of DKD. Metaflammation activates macrophages, and then secretes cytokines such as TNF-α, IL-1β to regulate immunity, afterwards the excessive activation of immune cells will also stimulate the inflammatory response (). There is a causal relationship between inflammation and insulin resistance, pro-inflammatory cytokines have been shown to mediate insulin resistance (; ). A meta-analysis suggested that C. sinensis combined with ACEI/ARB in patients with III to IV stage of DKD was effective to alleviate proteinuria, inflammation, and dyslipidemia by comparing 24-h proteinuria, urinary albumin excretion rate, microalbuminuria, serum creatinine, blood urea nitrogen, C-reactive protein, serum triglycerides, total cholesterol (). Recent DKD studies have focused more on inflammation, thus studying the anti-inflammatory mechanisms of TCM has also provided a new perspective on treatment progress. The extracellular polysaccharides (EPS) extracted from C. sinensis mycelial fermentation could suppress the inflammatory NF-κB pathway by inhibiting the expression of pro-inflammatory cytokines TNF-α and iNOS, and improving the expression of the anti-inflammatory regulator IL-10 in LPS-induced mice models ().
NADPH oxidase (NOX) plays a prominent role in inflammation, and is one of the main sources of ROS in biological systems (). As one of the members of NOX family, NOX4 is highly expressed in kidney, and recently, NOX1 has also been found in kidney (). Exposure to hyperglycemia, the expression of NOX4 in mouse proximal renal tubular cells is increased, using NOX1/4 inhibitors (GKT136901) or NOX4 siRNA could block the damage of hyperglycemia to kidney, and reduce the production of proteinuria (). Cordycepin could reverse the albumin-induced epithelial-to-mesenchymal transition (EMT) in HK-2 cells via reducing the expression of Rac1, NOX4, p22phox, p47phox, and inhibiting the formation of ROS to alleviate inflammation and oxidative stress (). TNF and TNF receptor-1 (TNFR1) participate in the recruitment of NOX1, which is involved in inflammation, cell proliferation, and immune defense, the binding of TNF homotrimer to TNF-R1 initiates the binding of the adaptor protein, then recruits other effector proteins to form the TNF-R1 signaling complex, leading to the activation of multiple pathways, and then producing ROS to initiate inflammation (; ). Based on a network pharmacological study, TNF is the crucial target in the treatment of DKD by C. sinensis (). And CPS-F, which was extracted from C. sinensis, could reduce the expression of pro-inflammatory cytokines and the production of ROS in human MCs by relying on TNF-R1, and inhibiting the activity of NOX1 to exert anti-inflammatory activity ().
In recent years, it has been demonstrated that the activation of purinergic 2X7 receptor (P2X7R) and nucleotide-binding oligomerization domain-like receptor protein 3 (NLRP3) inflammasome in podocytes are associated with the pathogenesis of DKD (; ). Robert et al. identified that P2X7R was highly expressed in renal biopsy specimens from patients with DKD, and the expression rate of glomerular P2X7R was about 50% (). The activation of P2X7R on M1 polarized pro-inflammatory macrophages, inducing the assembly of NLRP3 inflammasome, and then resulting in the release of pro-inflammatory factors and generation of inflammation (). Therefore, antagonizing P2X7R may become a new type of anti-inflammatory therapy. Extensive evidence on C. sinensis involved improving DKD via inhibiting P2X7R/NLRP3 inflammasome axis activation. It could down-regulate the expression of P2X7R, and NLRP3 inflammasome (including NLRP3, ASC, caspase-1) in vivo and in vitro experiments, and the expression of downstream factors IL-1β and IL-18 was also significantly decreased, C. sinensis exerted an anti-inflammatory effect by antagonizing the P2X7R/NLRP3 inflammasome axis to relieve podocytes damage in DKD (). C. sinensis can alleviate inflammation in varieties of ways to delay the progression of DKD, and the active constituents contained in it are vital to the anti-inflammatory agents in the pipeline.
3.3 Immunomodulatory Activity on Macrophages
C. sinensis regulates immunomodulatory activity to improve DKD may be primarily concentrated on its polysaccharides and nucleoside components. The immunomodulatory effect of natural plant polysaccharides has been recognized (). The activation of macrophages is an important event in immune response, and the infiltration of macrophages is related to the progression of DKD to ESRF (). Plant polysaccharides can regulate the balance of pro- and anti-inflammatory cytokines secreted by macrophages to normalize the immunity (; ). Polysaccharides activate macrophages by binding to specific receptors on the surface of macrophages, then initiating a series of intracellular signaling cascade reactions. They exert immunomodulatory effects by regulating the production of ROS, secretion of cytokines and chemokines, cell proliferation and phagocytic activity of macrophages (). Activated macrophages can be polarized into classically activated M1 and alternatingly activated M2 forms, where M2 cells have anti-inflammatory activity, abrogate the Th1 response, promote the Th2 response, release inflammatory substances, and promote epithelial and vascular repair (; ). C. sinensis could promote macrophages polarize towards an M2 phenotype to inhibit the inflammatory response, and regulate the production of cytokines in RAW264.7 cells through the MAPK and PI3K/Akt signaling pathways, exerting immunomodulatory activity on macrophages (). The balance of pro- and anti-inflammatory activities exerted by M1/M2 macrophages plays a pivotal role in the regulation of immune system (), cordycepin and adenosine could alter the phenotypic conversion of macrophages by reducing the expression of pro-inflammatory factors and chemokines, such as IL-1β, IL-6, TNF-α, RANTES, CX3CL1, and increasing the expression of anti-inflammatory cytokines, such as IL-1ra, IL-10, TGF-β (). By the way, the polarization of M2 macrophages can induce the occurrence of EMT and fibrosis, and M2 macrophages can promote the secretion of TGF-β, which is generally recognized as the typical pro-fibrosis factor and an anti-inflammatory factor (; ). C. sinensis up-regulated the mRNA levels of anti-inflammatory mediator (IL-10), and suppressed the mRNA levels of pro-inflammatory mediator (IL-1β) and the production of NO in LPS-induced RAW264.7 cells, regulating pro- and anti-inflammatory mediators to balance M1/M2 macrophages and avoiding excessive polarization of macrophages to exert immunomodulatory effect (). It was demonstrated that cordycepin could inhibit the expression of TNF-α, IL-6, IL-1β, and mediate the immune responses in macrophages, decrease the expression of diabetes regulating genes (11β-HSD1, PPARγ) in activated macrophages, finally play the immunomodulatory effect (). In summary, C. sinensis is closely linked to anti-inflammatory activity in regulating the immunity of macrophages. The C. sinensis preparations and their extracts are expected to become potential therapeutic agents for regulating metabolic inflammatory diseases.
Under the guidance of TCM theory, as a tonic, C. sinensis may also have a certain relationship with its regulation of T cells. The balance between effector T cells and regulatory T cells plays a regulatory role in the pathogenesis of DKD (). Lo et al. found that the polysaccharides extracted from the fermented mycelium of C. sinensis could increase the weight of the thymus gland in diabetic rats, and enhance the immunity (). One study has reported that C. sinensis could regulate the ratio of CD4+CD25+FoxP3+ regulatory T (T reg) cells and Th17 cells in spleen and pancreatic lymph nodes of non-obese diabetic mice, thereby inhibiting DM (). However, the regulation effect of C. sinensis on the balance of T cells in DKD is less, and further researches remain to be studied.
3.4 Anti-Oxidant Activity
Due to long-term exposure to high glucose environment, excessive amounts of superoxide, NO and other reactive oxygen substances are produced in cells, resulting in the decrease of endogenous and exogenous anti-oxidants, which cannot interact with ROS to counteract oxidative damage of cells (; ). The overproduction of ROS contributes to the microvascular damage, combines with oxidative stress, inducing the cellular apoptosis in DKD (). Hence, it is crucial to reduce the production of ROS by using anti-oxidant agents. It has been reported that C. sinensis has anti-oxidant effect (). Fatma et al. found that C. sinensis could exert powerful anti-oxidant effect to significantly reduce the pancreatic malondialdehyde levels and increase the serum anti-oxidant property in vitro and in vivo experiments (). And the anti-oxidant effect of C. sinensis might due to inhibit the production of ROS via the interference of C. sinensis extracts in ERK and Akt pathways ().
ROS can induce the influence of unsaturated fatty acids, and then induce the occurrence of lipid peroxidation, subsequently resulting in a decrease in fluidity of podocytes membranes, eventually with consequent damage of the structures and functions of the cell membranes (; ; ). The extracts of C. sinensis could attenuate lipid peroxidation and scavenge free radicals, while the enriched fraction of polysaccharides had even stronger anti-oxidant activity (). A current study indicated that the anti-oxidant activity of C. sinensis was achieved by melanin, it could scavenge DPPH• and the chelating ability on ferrous ions (). A study found that the phenols and flavonoids contained in Indian Himalayan isolate of C. sinensis (AECS) maybe the main components to exert anti-oxidant activity, AECS could significantly inhibit the release of TNF-α and IL-1β, and suppress the production of NO in LPS-induced THP1 cells (). Moreover, the rich unsaturated fatty acids in low-density lipoprotein (LDL) are susceptible to oxidative degeneration under cyclic oxidative conditions, and C. sinensis could reduce the occurrence of cardiovascular events in DKD by protecting the oxidation of LDL ().
There were accumulating evidence demonstrated that excessive albumin could activate NOX via Rac1, thus stimulating the production of ROS, and overproduction of ROS and NOX maybe take part in EMT induced by albumin (; ). Cordycepin could suppress oxidative stress damage and protect HK-2 cells by significantly inhibiting the expression of NADPH system constituent proteins, the production of ROS and the activity of NOX (). C. sinensis can scavenge free radicals and relieves the hyperactive oxidative systems in oxidative stress to protect the impaired kidney.
Anti-Fibrotic Activity
Renal interstitial fibrosis (RIF) is the ultimate outcome of DKD. The interaction of hemodynamic and metabolic factors leads to increased intraglomerular pressure and actives vasoactive hormone pathway, which activates the secretion of proliferation and fibrosis-promoting cytokines, such as prosclerotic cytokine, TGF-β and the permeability enhancing growth factor, vascular endothelial growth factor (VEGF), ultimately leads to changes in kidney permeability and accumulation of extracellular matrix (ECM) and results in fibrosis (; ). EMT plays an imperative role in the progress of fibrosis formation, and TGF-β is the key promoter of EMT. TGF-β induces the tubular epithelial cells turn into myofibroblasts, chronic inflammation, and leads to the production and accumulation of ECM (; ). At present, the anti-fibrotic treatment of C. sinensis mainly focused on regulating EMT and TGF-β. The nucleoside/nucleobase-rich extract from C. sinensis could significantly alleviate the development of DKD by inhibiting the progression of EMT and the accumulation of ECM via suppressing p38/ERK signaling pathway, together with decreased expression of fibrosis-related protein such as fibronectin and collagen Ⅰ (). Similarly, C. sinensis could mitigate the fibrosis by inhibiting the expression of Bcl-2-associated athanogene 3 (BAG3) and α-SMA in unilateral ureteral obstruction (UUO) rats, and regulating the formation of EMT ().
As an anti-inflammatory factor, TGF-β1 is also a typical pro-fibrotic factor and involved in the TGF-β/Smad signaling pathway, regulating the transcription of TGF-β1-reactive genes, interruption of any step in this cascading process may lead to the blocking of TGF-β1 signaling pathway, which leads to the blocking of myofibroblast activation (). Hence, the agents for blockage TGF-β1/Smad signaling pathway are important to alleviate fibrosis. C. sinensis could exert anti-fibrotic activity by mediating TGF-β1/Smad signaling pathway, and attenuate renal fibrosis in 5/6 nephrectomy rats by abrogating the expression of TGF-β1, Smad2/3, TβRⅠ, TβRⅡ, p-Smad2/3, α-SMA, and FSP1, and upregulated Smad7 to inhibit EMT (). As mentioned above, 3′-deoxyadenosine, also known as cordycepin, was identified as the mainly anti-fibrotic active biology constituent in C. sinensis, acting by interfering with profibrotic Smad signaling in vitro and in vivo (). Another study indicated that cordycepin could effectively upregulate the anti-fibrosis factor hepatocyte growth factor (HGF) at both the gene and protein levels in NRK-49F cells to mediate the blockage of Smad2/3 transfer from cytoplasmic to the nucleus, and inhibited the conversion of quiescent interstitial fibroblasts into myofibroblasts by blocking the nuclear translocation of Smad2/3 (). CPS-2, a polysaccharide extracted from C. sinensis could inhibit the PDGF-BB-induced proliferation of MCs through PDGF/ERK and TGF-β1/Smad signaling pathway, and inhibit the expression of α-SMA, PDGFRβ, TGF-β1, and Smad3, exerting the nephroprotection (). Reversing EMT is a treatment option, which can slow the process of fibrosis and prevent the progression of DKD to ESRF, and the active components of C. sinensis, including cordycepin, have an advantage in mitigating renal fibrosis, especially early intervention.
Regulation of Apoptosis
Apoptosis is one of the mechanisms of renal parenchymal cell reduction in the development of DKD, elimination of functional cells by apoptosis can induce renal insufficiency. In the progression of DKD, apoptosis can be induced by the increase of oxidative stress, and in the advanced DKD, with the progression of glomerular sclerosis, the number of apoptosis is increased and the renal function is gradually deteriorated (). It is indicated that C. sinensis can positively affect the homeostasis of apoptosis (), but the specific mechanism of regulating apoptosis in DKD remains to be explored. Klotho is a highly expressed anti-aging protein in kidney, which can inhibit oxidative stress by activating the Nrf2 signaling pathway, thereby protecting podocytes apoptosis in DKD (). Capase-3 plays an important role in the process of apoptosis, and in the early stage of apoptosis, the activation of capase-3 can lyse the corresponding cytoplasmic nucleus substrate, eventually leading to apoptosis (). TANG et al. demonstrated that the extracts of C. sinensis could suppress the apoptosis of NRK-52E cells by increasing the expression of Klotho, decreasing the expression of p53 and p21, and inhibiting the activation of capsase-3 (). And C. sinensis had been shown could inhibit Hbx-induced apoptosis in HK-2 cells by suppressing the PI3K/Akt-Bcl-2 signaling cascades (). Although it did not occur in DKD, the regulation of renal tubular epithelial cells apoptosis could still be used as a reference to lay the foundation for future research.
The pathological changes of DKD include mesangial proliferation, which is also an important reason for the increase of mesangial matrix and the abnormal synthesis and deposition of ECM (). H1-A, a kind of polysaccharides extracted from C. sinensis was found to inhibit mesangial proliferation and protect MCs from cytolysis at high concentrations of DMSO, and possibly mediate the tyrosine phosphorylation of anti-apoptotic factors Bcl-2 and Bcl-XL to promote apoptosis (). In contrast to inhibiting apoptosis in renal tubular epithelial cells, C. sinensis can promote apoptosis in MCs, which may be related to the pathology of DKD as thickening of the basement membrane and deposition of the mesangial matrix. Different cells have different pathological changes in the pathogenesis of DKD, and the effect of apoptosis has different meanings in different renal cells. In conclusion, it is necessary to continue to study the mechanism of C. sinensis regulating apoptosis in different renal intrinsic cells, and providing a new therapeutic target for the treatment of DKD.
The Clinical Use of Cordyceps sinensis in Treating Diabetic Kidney Disease
At present, three major cordyceps preparations, Bailing capsule (BLC), Zhiling capsule (ZLC), and Jinshuibao capsule (JSBC) has been approved for clinical treatment of DKD in China ().
Additional application of all three cordyceps preparations have been proved beneficial in treatment of DKD. Clinical studies have found that the combination of cordyceps preparations (BLC) with ACEI/ARB or SGLT2 inhibitors could significantly reduce the excretion of urinary protein, alleviate kidney damage, and delay the progression of DKD compared with the use of ACEI/ARB or SGLT2 inhibitors alone (; ). In addition to improving kidney function, some scholars have made research on cordyceps preparations in improving inflammation, oxidative stress, and immune regulation of DKD patients. A previous study has shown that BLC was able to inhibit aldose reductase (AR), thereby inhibiting the polyol pathway in DKD (). Specifically, Li et al. used BLC combined with dapagliflozin to treat patients with DKD for 12 weeks, the renal function indicators in the combination treatment group were significantly better than dapagliflozin alone, and the ocular vascular lesions of DKD patients were also alleviated (). Li et al. indicated that compared with the use of irbesartan alone, combined with BLC could significantly improve the micro-inflammatory state and oxidative stress response of DKD patients, with reduce levels of TNF-α, CRP, ROS and advanced protein oxidation product (AOPPS), and increased CD4+ and CD4+/CD8+ levels to regulate immune disorders (). JSBC combined with ACEI/ARB could effectively raise the total effective rate, reduce the 24 h urinary protein (24 h-UTP), urinary protein excretion rate and serum creatinine (Scr), and regulate glycolipid metabolism, the common using dose was from 3 to 6 capsules three times daily based on age (). The combination of JSBC and irbesartan could also effectively reduce endothelin-1 (ET-1), IL-6, TNF-α levels, and increase the expression of NO to improve vascular endothelial function and alleviate micro-inflammatory state in patients with DKD (). Similarly, ZLC combined with telmisartan could significantly reduce the levels of Scr, 24 h-UTP, TNF-α, CRP, IL-6 and ET, increase NO levels, improve glomerular vasomotor function, and delay the progression of DKD (). At present, relevant studies have not found adverse reactions to the prolonged use of cordyceps preparations (), but it still needs to be supported by more high-quality randomized controlled trials. And there is a lack of high-quality evidence on the occurrence of cardiovascular events associated with DKD (; ).
Some researched aimed to compare the differences of three major cordyceps preparations. JSBC, BLC and ZLC are prepared by the fermentation of Paecilomyces hepiali (strain Cs-4), Hirsutella sinensis (strain Cs-C-Q80) and Mortierella SP, and 64, 39, and 56 components were identified in the essential oils of JSBC, BLC, and ZLC, respectively (). 5,6-Dihydro-6-pentyl-2H-pyran-2-one (massoia lactone) was the main component in the volatiles of JSBC, and pyrazinamide was characteristic in BLC. Besides, ZLC had the highest proportion of fatty acid compounds up to 27.1%, which could effectively enhance cell function and improved the metabolic capacity of cells (; ). Meantime, the analysis of nucleosides and bases in fermented cordyceps preparations found that the content of guanosine, uridine and adenosine in ZLC was comparable, and it was higher than that in BLC and JSBC, while the 3 bases in BLC were the lowest (). However, in spite of the differences between compositions of 3 cordyceps preparations, no clinical studies are comparing the efficacy of the three preparations in the treatment of DKD, and whether there are different effects between them is still worth exploring. The differently using conditions of the 3 cordyceps preparations remain one of the problems that need to be explored in clinical and future experimental studies. It is worth exploring the conditions among the three preparations which are applied to DKD and whether there are differences between their effects, in order to facilitate the best application in clinic.
Conclusion
At present, the clinical treatment of CKD is focused on symptomatic treatment. The first-line treatments are mainly based on RAS blockers. However, there will be rising limitations in the use of drugs with the decline of renal function until it turns into ESRF. The emergence of Chinese herbal medicines and various Chinese patent medicines as the adjuvant drugs can effectively alleviate the side effects of drugs and slow the progression of kidney function. This review focused on mechanisms of C. sinensis and its extracts in the treatment of DKD (Table 2, Figure 2). Clinical applications and its efficacy of Chinese patent medicines made from C. sinensis in treatment of DKD were also reviewed.
TABLE 2
| Effects | Materials | Subjects | Targets | Reference |
|---|---|---|---|---|
| Anti-hyperglycemia effects | CS-F10 | STZ-induced and epinephrine-induced hyperglycemic mice | GLUT2 | |
| β-sitosterol | high-fat diet and sucrose-induced type-2 diabetic rats | SOD, GST, CAT, GR, GSH, GPX, IRβ, GLUT4 | ||
| Anti-inflammatory effect | EPS | LPS-induced THP-1 cells, LPS-induced RAW264.7 cells, LPS-induced mice | NO, NF-κB, TNF-α, IL-1β, IL-10, iNOS | |
| CPS-F | PDGF-BB induced HMCs | ROS, TNF-α, TNF-R1, MCP-1, NOX1, PDGFRβ | ||
| C. sinensis | STZ-induced DKD rats, high-glucose exposed podocytes | P2X7R, NLRP3, ASC, caspase-1, IL-1β, IL-18, nephrin, podocin, WT-1, desmin | ||
| Cordycepin | Albumin-induced EMT in HK-2 cells | E-cadherin, α-SMA, ROS, NOX4, p22phox, p47phox, Rac1-GTP | ||
| Immunomodulatory effect | Intracellular polysaccharides | LPS-induced RAW264.7 cells | TNF-α, IL-6, IL-1β, IL-10, TGF-β1, iNOS, NO, ERK, JNK, p38, AKT | |
| Cordycepin, adenosine | LPS-induced RAW264.7 cells | IL-1β, IL-6, TNF-α, RANTES, CX3CL1, IL-1ra, IL-10, TGF-β | ||
| C. sinensis | Non-obese diabetic mice | CD4+CD25+FoxP3+ T reg cells, Th17 cells | ||
| Cordycepin | LPS-induced RAW264.7 cells | NO, IL-1β, IL-6, TNF-α, 11β-HSD1, PPARγ, ICAM-1, B7-1/-1 | ||
| Anti-oxidant effect | CPS-F | PDGF-BB induced HMCs | ROS, TNF-α, TNFR1, MCP-1, NOX1, PDGFRβ | |
| C. sinensis from India | LPS-induced THP1 cells | TNF-α, IL-1β, NO | ||
| Cordycepin | Albumin-induced EMT in HK-2 cells | E-cadherin, α-SMA, ROS, NOX4, P22phox, P47phox, Rac1-GTP | ||
| Anti-fibrotic effect | nucleoside/nucleobase-rich extract | STZ-induced diabetic mice, high-glucose exposed HK-2 cells | E-cadherin, α-SMA, FN, Col Ⅰ, p38, ERK, JNK | |
| C. sinensis | UUO rats | α-SMA, BAG3 | ||
| C. sinensis | 5/6 subtotal nephrectomy rats | TGF-β1, Smad2, Smad3, TβRⅠ, TβRⅡ, α-SMA, FSP1, Smad7 | ||
| Cordycepin | TGF-β1or BMP-4 induced NRK-52E cells/MCs, UUO mice | TGF-β, BMP-4, Col Ⅰ, ColⅣ, Smad1, Smad2, Smad3, eIF2α, CAGA, BRE | ||
| Cordycepin | TGF-β1 induced NRK-49F cells | α-SMA, FN, HGF, c-MET, TGF-β1, Smad2, Smad3 | ||
| CPS-2 | PDGF-BB induced HMCs | α-SMA, PDGFRβ, TGF-β1, Smad3, ERK, TGFβR1 | ||
| Regulation of apoptosis | C. sinensis | Ang Ⅱ induced NRK-52E cells | Kl, p53, p21, caspase-3 | |
| C. sinensis | HBx induced HK-2 cells | Capse-3, capse-9, PI3K, Akt, Bax, Bcl-2 | ||
| H1-A | IL-1 and PDGF-BB induced HMCs | Bcl-2, Bcl-XL |
Major effects and targets of Cordyceps Sinensis in Diabetic Kidney Disease.
FIGURE 2
However, some important problems should be further investigated. For example, in the regulation of apoptosis of C. sinensis, why different regulatory effects on different renal parenchymal cells remain to be explored. And the dose control of the extracted C. sinensis active substance should also be studied with a view to selecting the optimal clinical therapeutic dose. Moreover, the poly-component and multi-target effect of TCM is a double-edged sword. Although several main active ingredients, such as cordycepin, adenosine, and various polysaccharides, had been identified, there are still many components with unclear effects and functions. Therefore, it is suggested that we should continue to explore the potential active components and therapeutic effects of C. sinensis in the future. Pharmacological research on its main active extracts to candidate new agents and therapeutic targets are also imperative for its multiple applications in the clinic. Besides, considering the high prices of C. sinensis, more investigates are needed to reduce the economic burden on patients, including but not limited to artificial cultivation and development of new extraction methods. In addition, whether there are different effects among them still unclear and more research should be done to find the best conditions for each cordyceps preparation. High-quality prospective clinical trials with follow-up are also needed to provide convincing evidence of its safety and efficacy. We think that these explorations will provide new insight into clinical application of C. sinensis in treatment of DKD.
Statements
Author contributions
WL collected related studies and drafted the manuscript. YG, YZ, FY and XL collected related studies. NZ was responsible for the final review of the manuscript. All authors read and approved the final manuscript.
Funding
The study was supported by the National Natural Science Foundation of China (NO. 81973801); Capital’s Funds for Health Improvement and Research (NO. 2018-1-4161); Science and Technology Innovation Project of China Academy of Chinese Medical Sciences (NO. CI2021A01609).
Conflict of interest
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1
Abou-HanyH. O.AtefH.SaidE.ElkashefH. A.SalemH. A. (2018). Crocin Mediated Amelioration of Oxidative Burden and Inflammatory Cascade Suppresses Diabetic Nephropathy Progression in Diabetic Rats. Chemico-biol. interactions284, 90–100. 10.1016/j.cbi.2018.02.001
2
AlicicR. Z.RooneyM. T.TuttleK. R. (2017). Diabetic Kidney Disease: Challenges, Progress, and Possibilities. Clin. J. Am. Soc. Nephrol.12, 2032–2045. 10.2215/CJN.11491116
3
AlnemriE. S.LivingstonD. J.NicholsonD. W.SalvesenG.ThornberryN. A.WongW. W.et al (1996). Human ICE/CED-3 Protease Nomenclature. Cell.87, 171. 10.1016/s0092-8674(00)81334-3
4
AnJ.NiuF.SimJ. J. (2021). Cardiovascular and Kidney Outcomes of Spironolactone or Eplerenone in Combination with ACEI/ARBs in Patients with Diabetic Kidney Disease. Pharmacotherapy41, 998–1008. 10.1002/phar.2633
5
ArtuncF.SchleicherE.WeigertC.FritscheA.StefanN.HäringH. U. (2016). The Impact of Insulin Resistance on the Kidney and Vasculature. Nat. Rev. Nephrol.12, 721–737. 10.1038/nrneph.2016.145
6
AshrafS. A.ElkhalifaA. E. O.SiddiquiA. J.PatelM.AwadelkareemA. M.SnoussiM.et al (2020). Cordycepin for Health and Wellbeing: A Potent Bioactive Metabolite of an Entomopathogenic Cordyceps Medicinal Fungus and its Nutraceutical and Therapeutic Potential. Molecules25, 2735. 10.3390/molecules25122735
7
BelskaN. V.GurievA. M.DaniletsM. G.TrophimovaE. S.UchasovaE. G.LigatchevaA. A.et al (2010). Water-soluble Polysaccharide Obtained from Acorus calamus L. Classically Activates Macrophages and Stimulates Th1 Response. Int. Immunopharmacol.10, 933–942. 10.1016/j.intimp.2010.05.005
8
BuenzE. J.BauerB. A.OsmundsonT. W.MotleyT. J. (2005). The Traditional Chinese Medicine Cordyceps Sinensis and its Effects on Apoptotic Homeostasis. J. Ethnopharmacol.96, 19–29. 10.1016/j.jep.2004.09.029
9
CaoC.YangS.ZhouZ. (2020). The Potential Application of Cordyceps in Metabolic-Related Disorders. Phytother. Res.34, 295–305. 10.1002/ptr.6536
10
CaoX.ZhangP.YangJ. (2007). Efficacy of Jinshuibao Combined with Valsartan in the Treatment of Early Type 2 Diabetic Nephropathy. Chin. J. New Drugs16, 1303–1306.
11
ChangY.HsuW. H.LuW. J.JayakumarT.LiaoJ. C.LinM. J.et al (2015). Inhibitory Mechanisms of CME-1, a Novel Polysaccharide from the Mycelia of Cordyceps Sinensis, in Platelet Activation. Curr. Pharm. Biotechnol.16, 451–461. 10.2174/1389201016666150303152237
12
ChenG.GoeddelD. V. (2002). TNF-R1 Signaling: a Beautiful Pathway. Science296, 1634–1635. 10.1126/science.1071924
13
ChenP. X.WangS.NieS.MarconeM. (2013). Properties of Cordyceps Sinensis: A Review. J. Funct. Foods5, 550–569. 10.1016/j.jff.2013.01.034
14
ChenW.ZhangW.ShenW.WangK. (2010). Effects of the Acid Polysaccharide Fraction Isolated from a Cultivated Cordyceps Sinensis on Macrophages In Vitro. Cell. Immunol.262, 69–74. 10.1016/j.cellimm.2010.01.001
15
CowardR. J.WelshG. I.YangJ.TasmanC.LennonR.KoziellA.et al (2005). The Human Glomerular Podocyte Is a Novel Target for Insulin Action. Diabetes54, 3095–3102. 10.2337/diabetes.54.11.3095
16
Di VincenzoA.TanaC.El HadiH.PaganoC.VettorR.RossatoM. (2019). Antioxidant, Anti-inflammatory, and Metabolic Properties of Tocopherols and Tocotrienols: Clinical Implications for Vitamin E Supplementation in Diabetic Kidney Disease. Int. J. Mol. Sci.20, 5101. 10.3390/ijms20205101
17
DongC.YaoY. (2012). Isolation, Characterization of Melanin Derived from Ophiocordyceps Sinensis, an Entomogenous Fungus Endemic to the Tibetan Plateau. J. Biosci. Bioeng.113, 474–479. 10.1016/j.jbiosc.2011.12.001
18
DongC. H.YaoY. J. (2008). In Vitro evaluation of Antioxidant Activities of Aqueous Extracts from Natural and Cultured Mycelia of Cordyceps Sinensis. Leb. Wiss Technol.41, 669–677. 10.1016/j.lwt.2007.05.002
19
DongZ.SunY.WeiG.LiS.ZhaoZ. (2019). A Nucleoside/Nucleobase-Rich Extract from Cordyceps Sinensis Inhibits the Epithelial-Mesenchymal Transition and Protects against Renal Fibrosis in Diabetic Nephropathy. Molecules24, 4119. 10.3390/molecules24224119
20
DuF.LiS.WangT.ZhangH. Y.ZongZ. H.DuZ. X.et al (2015). Cordyceps Sinensis Attenuates Renal Fibrosis and Suppresses BAG3 Induction in Obstructed Rat Kidney. Am. J. Transl. Res.7, 932–940.
21
EkorM. (2014). The Growing Use of Herbal Medicines: Issues Relating to Adverse Reactions and Challenges in Monitoring Safety. Front. Pharmacol.4, 177. 10.3389/fphar.2013.00177
22
El Zahraa Z El AshryF.MahmoudM. F.El MaraghyN. N.AhmedA. F. (2012). Effect of Cordyceps Sinensis and Taurine Either Alone or in Combination on Streptozotocin Induced Diabetes. Food Chem. Toxicol.50, 1159–1165. 10.1016/j.fct.2011.12.020
23
FitchettD. (2019). A Safety Update on Sodium Glucose Co-transporter 2 Inhibitors. Diabetes Obes. Metab.21, 34–42. 10.1111/dom.13611
24
GlassockR. J.WarnockD. G.DelanayeP. (2017). The Global Burden of Chronic Kidney Disease: Estimates, Variability and Pitfalls. Nat. Rev. Nephrol.13, 104–114. 10.1038/nrneph.2016.163
25
GorinY.WauquierF. (2015). Upstream Regulators and Downstream Effectors of NADPH Oxidases as Novel Therapeutic Targets for Diabetic Kidney Disease. Mol. Cells38, 285–296. 10.14348/molcells.2015.0010
26
GuL.JohnoH.NakajimaS.KatoH.TakahashiS.KatohR.et al (2013). Blockade of Smad Signaling by 3'-deoxyadenosine: a Mechanism for its Anti-fibrotic Potential. Lab. Investig.93, 450–461. 10.1038/labinvest.2013.4
27
HaskóG.SzabóC.NémethZh.KvetanV.PastoresS. M.ViziE. S. (1996). Adenosine Receptor Agonists Differentially Regulate IL-10, TNF-Alpha, and Nitric Oxide Production in RAW 264.7 Macrophages and in Endotoxemic Mice. J. Immunol.157, 4634–4640.
28
HeP.LeiJ.MiaoJ. N.WuD.WangC. (2020). Cordyceps Sinensis Attenuates HBx-induced C-ell A-poptosis in HK-2 C-ells through S-uppressing the PI3K/Akt P-athway. Int. J. Mol. Med.45, 1261–1269. 10.3892/ijmm.2020.4503
29
HotamisligilG. S.ShargillN. S.SpiegelmanB. M. (1993). Adipose Expression of Tumor Necrosis Factor-Alpha: Direct Role in Obesity-Linked Insulin Resistance. Science259, 87–91. 10.1126/science.7678183
30
HuH.XiaoL.ZhengB.WeiX.EllisA.LiuY. M. (2015). Identification of Chemical Markers in Cordyceps Sinensis by HPLC-MS/MS. Anal. Bioanal. Chem.407, 8059–8066. 10.1007/s00216-015-8978-6
31
HuangC. W.HongT. W.WangY. J.ChenK. C.PeiJ. C.ChuangT. Y.et al (2016). Ophiocordyceps Formosana Improves Hyperglycemia and Depression-like Behavior in an STZ-Induced Diabetic Mouse Model. BMC Complement. Altern. Med.16, 310. 10.1186/s12906-016-1278-7
32
JhaJ. C.BanalC.ChowB. S.CooperM. E.Jandeleit-DahmK. (2016). Diabetes and Kidney Disease: Role of Oxidative Stress. Antioxid. Redox Signal25, 657–684. 10.1089/ars.2016.6664
33
JiaJ. M.MaX. C.WuC. F.WuL. J.HuG. S. (2005). Cordycedipeptide A, a New Cyclodipeptide from the Culture Liquid of Cordyceps Sinensis (Berk.) Sacc. Chem. Pharm. Bull. (Tokyo)53, 582–583. 10.1248/cpb.53.582
34
JiaJ. M.TaoH. H.FengB. M. (2009). Cordyceamides A and B from the Culture Liquid of Cordyceps Sinensis (BERK.) SACC. Chem. Pharm. Bull. (Tokyo)57, 99–101. 10.1248/cpb.57.99
35
JiaG.Whaley-ConnelA.SowersJ. R. (2018). Diabetic Cardiomyopathy: A Hyperglycaemia-And Insulin-Resistance-Induced Heart Disease. Diabetologia61, 21–28. 10.1007/s00125-017-4390-4
36
KaiZ.YongjianL.ShengG.YuL. (2015). Effect of Dongchongxiacao (Cordyceps) Therapy on Contrast-Induced Nephropathy in Patients with Type 2 Diabetes and Renal Insufficiency Undergoing Coronary Angiography. J. Tradit. Chin. Med.35, 422–427. 10.1016/s0254-6272(15)30119-9
37
KanasakiK.TaduriG.KoyaD. (2013). Diabetic Nephropathy: the Role of Inflammation in Fibroblast Activation and Kidney Fibrosis. Front. Endocrinol. (Lausanne)4, 7. 10.3389/fendo.2013.00007
38
KarallieddeJ.GnudiL. (2016). Diabetes Mellitus, a Complex and Heterogeneous Disease, and the Role of Insulin Resistance as a Determinant of Diabetic Kidney Disease. Nephrol. Dial. Transpl.31, 206–213. 10.1093/ndt/gfu405
39
KihoT.HuiJ.YamaneA.UkaiS. (1993). Polysaccharides in Fungi. XXXII. Hypoglycemic Activity and Chemical Properties of a Polysaccharide from the Cultural Mycelium of Cordyceps Sinensis. Biol. Pharm. Bull.16, 1291–1293. 10.1248/bpb.16.1291
40
KihoT.OokuboK.UsuiS.UkaiS.HiranoK. (1999). Structural Features and Hypoglycemic Activity of a Polysaccharide (CS-F10) from the Cultured Mycelium of Cordyceps Sinensis. Biol. Pharm. Bull.22, 966–970. 10.1248/bpb.22.966
41
KimS. D. (2010). Isolation, Structure and Cholesterol Esterase Inhibitory Activity of a Polysaccharide, PS-A, from Cordyceps Sinensis. Jksabc53, 784–789. 10.3839/jksabc.2010.118
42
KimY. S.MorganM. J.ChoksiS.LiuZ. G. (2007). TNF-induced Activation of the Nox1 NADPH Oxidase and its Role in the Induction of Necrotic Cell Death. Mol. Cell.26, 675–687. 10.1016/j.molcel.2007.04.021
43
KwonY.-M.ChoS.-M.KimJ.-H.LeeJ.-H.LeeY.-A.LeeS.-J.et al (2001). Hypoglycemic Effect of Cordyceps Militaris. Korean J. Pharmacogn.32, 327–329.
44
LeiD.ChengchengL.XuanQ.YibingC.LeiW.HaoY.et al (2019). Quercetin Inhibited Mesangial Cell Proliferation of Early Diabetic Nephropathy through the Hippo Pathway. Pharmacol. Res.146, 104320. 10.1016/j.phrs.2019.104320
45
LiL.HeD.YangJ.WangX. (2011). Cordycepin Inhibits Renal Interstitial Myofibroblast Activation Probably by Inducing Hepatocyte Growth Factor Expression. J. Pharmacol. Sci.117, 286–294. 10.1254/jphs.11127fp
46
LiL. Q.SongA. X.YinJ. Y.SiuK. C.WongW. T.WuJ. Y. (2020). Anti-inflammation Activity of Exopolysaccharides Produced by a Medicinal Fungus Cordyceps Sinensis Cs-HK1 in Cell and Animal Models. Int. J. Biol. Macromol.149, 1042–1050. 10.1016/j.ijbiomac.2020.02.022
47
LiS. P.LiP.DongT. T.TsimK. W. (2001). Anti-oxidation Activity of Different Types of Natural Cordyceps Sinensis and Cultured Cordyceps Mycelia. Phytomedicine8, 207–212. 10.1078/0944-7113-00030
48
LiS. P.ZhangG. H.ZengQ.HuangZ. G.WangY. T.DongT. T.et al (2006). Hypoglycemic Activity of Polysaccharide, with Antioxidation, Isolated from Cultured Cordyceps Mycelia. Phytomedicine13, 428–433. 10.1016/j.phymed.2005.02.002
49
LiX.GaoL. (2021). Effect of Bailing Capsule Combined with Dapagliflozin on Diabetic Nephropathy. Lishizhen Med. Materia Medica Res.32, 355–357.
50
LiY.LiuY.HanX.JinH.MaS. (2019a). Arsenic Species in Cordyceps Sinensis and its Potential Health Risks. Front. Pharmacol.10, 1471. 10.3389/fphar.2019.01471
51
LiY.WangL.XuB.ZhaoL.LiL.XuK.et al (2021). Based on Network Pharmacology Tools to Investigate the Molecular Mechanism of Cordyceps Sinensis on the Treatment of Diabetic Nephropathy. J. Diabetes Res.2021, 8891093. 10.1155/2021/8891093
52
LiY.XuG. (2020). Clinical Efficacy and Safety of Jinshuibao Combined with ACEI/ARB in the Treatment of Diabetic Kidney Disease: A Meta-Analysis of Randomized Controlled Trials. J. Ren. Nutr.30, 92–100. 10.1053/j.jrn.2019.03.083
53
LiZ.ZhangG.ZhengS.ZhengJ.ZhangY.YuanP. (2019b). Effects of Bailing Capsule Combined with Irbesartan on Oxidative Stress, Inflammatory Response and Immune Function in Patients with Diabetic Nephropathy. J. Hainan Med. Univ.25, 670–673. 10.13210/j.cnki.jhmu.20190322.004
54
LiuJ.LiY.ZanK.ZhengJ.GuoL.MaS. (2016). A Comparative Study on the Content of Pb, Cd, as, Hg and Cu between Cultivated and Natural Cordyceps Sinensis. Chin. Pharm. Affa30, 912–918. 10.16153/j.1002-7777.2016.09.012
55
LiuY.LiQ. Z.LiL. D.ZhouX. W. (2021). Immunostimulatory Effects of the Intracellular Polysaccharides Isolated from Liquid Culture of Ophiocordyceps Sinensis (Ascomycetes) on RAW264.7 Cells via the MAPK and PI3K/Akt Signaling Pathways. J. Ethnopharmacol.275, 114130. 10.1016/j.jep.2021.114130
56
LiuY.WangJ.WangW.ZhangH.ZhangX.HanC. (2015). The Chemical Constituents and Pharmacological Actions of Cordyceps Sinensis. Evid. Based Complement. Altern. Med.2015, 575063. 10.1155/2015/575063
57
LoH. C.HsuT. H.TuS. T.LinK. C. (2006). Anti-hyperglycemic Activity of Natural and Fermented Cordyceps Sinensis in Rats with Diabetes Induced by Nicotinamide and Streptozotocin. Am. J. Chin. Med.34, 819–832. 10.1142/S0192415X06004314
58
LoH. C.TuS. T.LinK. C.LinS. C. (2004). The Anti-hyperglycemic Activity of the Fruiting Body of Cordyceps in Diabetic Rats Induced by Nicotinamide and Streptozotocin. Life Sci.74, 2897–2908. 10.1016/j.lfs.2003.11.003
59
LuQ.LiC.ChenW.ShiZ.ZhanR.HeR. (2018). Clinical Efficacy of Jinshuibao Capsules Combined with Angiotensin Receptor Blockers in Patients with Early Diabetic Nephropathy: A Meta-Analysis of Randomized Controlled Trials. Evid. Based Complement. Altern. Med.2018, 6806943. 10.1155/2018/6806943
60
LuZ.ZhongY.LiuW.XiangL.DengY. (2019). The Efficacy and Mechanism of Chinese Herbal Medicine on Diabetic Kidney Disease. J. Diabetes Res.2019, 2697672. 10.1155/2019/2697672
61
LuoY.YangS. K.ZhouX.WangM.TangD.LiuF. Y.et al (2015). Use of Ophiocordyceps Sinensis (Syn. Cordyceps Sinensis) Combined with Angiotensin-Converting Enzyme Inhibitors (ACEI)/angiotensin Receptor Blockers (ARB) versus ACEI/ARB Alone in the Treatment of Diabetic Kidney Disease: a Meta-Analysis. Ren. Fail37, 614–634. 10.3109/0886022X.2015.1009820
62
MantovaniA.SicaA.LocatiM. (2007). New Vistas on Macrophage Differentiation and Activation. Eur. J. Immunol.37, 14–16. 10.1002/eji.200636910
63
MatsudaH.AkakiJ.NakamuraS.OkazakiY.KojimaH.TamesadaM.et al (2009). Apoptosis-inducing Effects of Sterols from the Dried Powder of Cultured Mycelium of Cordyceps Sinensis. Chem. Pharm. Bull. (Tokyo)57, 411–414. 10.1248/cpb.57.411
64
MayerG. J.WannerC.WeirM. R.InzucchiS. E.Koitka-WeberA.HantelS.et al (2019). Analysis from the EMPA-REG OUTCOME® Trial indicates Empagliflozin May Assist in Preventing the progression of Chronic Kidney Disease in Patients with Type 2 Diabetes Irrespective of Medications that Alter Intrarenal Hemodynamics. Kidney Int.96, 489–504. 10.1016/j.kint.2019.02.033
65
MenziesR. I.BoothJ. W. R.MullinsJ. J.BaileyM. A.TamF. W. K.NormanJ. T.et al (2017). Hyperglycemia-induced Renal P2X7 Receptor Activation Enhances Diabetes-Related Injury. EBioMedicine19, 73–83. 10.1016/j.ebiom.2017.04.011
66
MűzesG.MolnárB.TulassayZ.SiposF. (2012). Changes of the Cytokine Profile in Inflammatory Bowel Diseases. World J. Gastroenterol.18, 5848–5861. 10.3748/wjg.v18.i41.5848
67
NiuY. J.TaoR. Y.LiuQ.TianJ. Y.YeF.ZhuP.et al (2010). Improvement on Lipid Metabolic Disorder by 3'-deoxyadenosine in High-Fat-Diet-Induced Fatty Mice. Am. J. Chin. Med.38, 1065–1075. 10.1142/S0192415X10008470
68
OlatunjiO. J.TangJ.TolaA.AuberonF.OluwaniyiO.OuyangZ. (2018). The Genus Cordyceps: An Extensive Review of its Traditional Uses, Phytochemistry and Pharmacology. Fitoterapia129, 293–316. 10.1016/j.fitote.2018.05.010
69
OlefskyJ. M.GlassC. K. (2010). Macrophages, Inflammation, and Insulin Resistance. Annu. Rev. Physiol.72, 219–246. 10.1146/annurev-physiol-021909-135846
70
OyarzúnC.GarridoW.AlarcónS.YáñezA.SobreviaL.QuezadaC.et al (2017). Adenosine Contribution to Normal Renal Physiology and Chronic Kidney Disease. Mol. Asp. Med.55, 75–89. 10.1016/j.mam.2017.01.004
71
PanM. M.ZhangM. H.NiH. F.ChenJ. F.XuM.PhillipsA. O.et al (2013). Inhibition of TGF-β1/Smad Signal Pathway Is Involved in the Effect of Cordyceps Sinensis against Renal Fibrosis in 5/6 Nephrectomy Rats. Food Chem. Toxicol.58, 487–494. 10.1016/j.fct.2013.04.037
72
ParcellA. C.SmithJ. M.SchulthiesS. S.MyrerJ. W.FellinghamG. (2004). Cordyceps Sinensis (CordyMax Cs-4) Supplementation Does Not Improve Endurance Exercise Performance. Int. J. Sport Nutr. Exerc Metab.14, 236–242. 10.1123/ijsnem.14.2.236
73
PatersonR. R. (2008). Cordyceps: a Traditional Chinese Medicine and Another Fungal Therapeutic Biofactory?Phytochemistry69, 1469–1495. 10.1016/j.phytochem.2008.01.027
74
PeleliM.CarlstromM. (2017). Adenosine Signaling in Diabetes Mellitus and Associated Cardiovascular and Renal Complications. Mol. Asp. Med.55, 62–74. 10.1016/j.mam.2016.12.001
75
PichlerR.AfkarianM.DieterB. P.TuttleK. R. (2017). Immunity and Inflammation in Diabetic Kidney Disease: Translating Mechanisms to Biomarkers and Treatment Targets. Am. J. Physiol. Ren. Physiol.312, F716–f731. 10.1152/ajprenal.00314.2016
76
PonnulakshmiR.ShyamaladeviB.VijayalakshmiP.SelvarajJ. (2019). In Silico and In Vivo Analysis to Identify the Antidiabetic Activity of Beta Sitosterol in Adipose Tissue of High Fat Diet and Sucrose Induced Type-2 Diabetic Experimental Rats. Toxicol. Mech. Methods29, 276–290. 10.1080/15376516.2018.1545815
77
QianG. M.PanG. F.GuoJ. Y. (2012). Anti-inflammatory and Antinociceptive Effects of Cordymin, a Peptide Purified from the Medicinal Mushroom Cordyceps Sinensis. Nat. Prod. Res.26, 2358–2362. 10.1080/14786419.2012.658800
78
RathorR.MishraK. P.PalM.AmitabhS.VatsP.KirarV.et al (2014). Scientific Validation of the Chinese Caterpillar Medicinal Mushroom, Ophiocordyceps Sinensis (Ascomycetes) from India: Immunomodulatory and Antioxidant Activity. Int. J. Med. Mushrooms16, 541–553. 10.1615/intjmedmushrooms.v16.i6.40
79
ReidyK.KangH. M.HostetterT.SusztakK. (2014). Molecular Mechanisms of Diabetic Kidney Disease. J. Clin. Investig.124, 2333–2340. 10.1172/JCI72271
80
RotterV.NagaevI.SmithU. (2003). Interleukin-6 (IL-6) Induces Insulin Resistance in 3T3-L1 Adipocytes and Is, like IL-8 and Tumor Necrosis Factor-Alpha, Overexpressed in Human Fat Cells from Insulin-Resistant Subjects. J. Biol. Chem.278, 45777–45784. 10.1074/jbc.M301977200
81
SabapathyV.StremskaM. E.MohammadS.CoreyR. L.SharmaP. R.SharmaR. (2019). Novel Immunomodulatory Cytokine Regulates Inflammation, Diabetes, and Obesity to Protect from Diabetic Nephropathy. Front. Pharmacol.10, 572. 10.3389/fphar.2019.00572
82
Sailaja DeviM. M.SureshY.DasU. N. (2000). M., Suresh, Y. & DasPreservation of the Antioxidant Status in Chemically-Induced Diabetes Mellitus by Melatonin. J. Pineal Res.29, 108–115. 10.1034/j.1600-079x.2000.290207.x
83
SarafidisP.FerroC. J.MoralesE.OrtizA.MalyszkoJ.HojsR.et al (2019). SGLT-2 Inhibitors and GLP-1 Receptor Agonists for Nephroprotection and Cardioprotection in Patients with Diabetes Mellitus and Chronic Kidney Disease. A Consensus Statement by the EURECA-M and the DIABESITY Working Groups of the ERA-EDTA. Nephrol. Dial. Transpl.34, 208–230. 10.1093/ndt/gfy407
84
SedeekM.NasrallahR.TouyzR. M.HébertR. L. (2013). NADPH Oxidases, Reactive Oxygen Species, and the Kidney: Friend and Foe. J. Am. Soc. Nephrol.24, 1512–1518. 10.1681/ASN.2012111112
85
ShahzadK.BockF.DongW.WangH.KopfS.KohliS.et al (2015). Nlrp3-inflammasome Activation in Non-myeloid-derived Cells Aggravates Diabetic Nephropathy. Kidney Int.87, 74–84. 10.1038/ki.2014.271
86
ShashidharM. G.GiridharP.Udaya SankarK.ManoharB. (2013). Bioactive Principles from Cordyceps Sinensis: A Potent Food Supplement - A Review. J. Funct. Foods5, 1013–1030. 10.1016/j.jff.2013.04.018
87
ShengX.DongY.ChengD.WangN.GuoY. (2020). Efficacy and Safety of Bailing Capsules in the Treatment of Type 2 Diabetic Nephropathy: a Meta-Analysis. Ann. Palliat. Med.9, 3885–3898. 10.21037/apm-20-1799
88
ShiB.WangZ.JinH.ChenY. W.WangQ.QianY. (2009). Immunoregulatory Cordyceps Sinensis Increases Regulatory T Cells to Th17 Cell Ratio and Delays Diabetes in NOD Mice. Int. Immunopharmacol.9, 582–586. 10.1016/j.intimp.2009.01.030
89
ShinS.LeeS.KwonJ.MoonS.LeeS.LeeC. K.et al (2009a). Cordycepin Suppresses Expression of Diabetes Regulating Genes by Inhibition of Lipopolysaccharide-Induced Inflammation in Macrophages. Immune Netw.9, 98–105. 10.4110/in.2009.9.3.98
90
ShinS.MoonS.ParkY.KwonJ.LeeS.LeeC. K.et al (2009b). Role of Cordycepin and Adenosine on the Phenotypic Switch of Macrophages via Induced Anti-inflammatory Cytokines. Immune Netw.9, 255–264. 10.4110/in.2009.9.6.255
91
SidhomE. H.KimC.Kost-AlimovaM.TingM. T.KellerK.Avila-PachecoJ.et al (2021). Targeting a Braf/Mapk Pathway Rescues Podocyte Lipid Peroxidation in CoQ-Deficiency Kidney Disease. J. Clin. Investig.131, e141380. 10.1172/JCI141380
92
SnelM.JonkerJ. T.SchoonesJ.LambH.De RoosA.PijlH.et al (2012). Ectopic Fat and Insulin Resistance: Pathophysiology and Effect of Diet and Lifestyle Interventions. Int. J. Endocrinol.2012, 983814. 10.1155/2012/983814
93
SoldatosG.CooperM. E. (2008). Diabetic Nephropathy: Important Pathophysiologic Mechanisms. Diabetes Res. Clin. Pract.82, S75–S79. 10.1016/j.diabres.2008.09.042
94
SongY.HuP.ZhaoS.ZhangH.JiangZ.WangY.et al (2018). Distinction of Fermented Cordyceps Products from Different Strains and Analysis of Their Volatile Components by HS-SPME/GC-MS Combined Wtih Chemometrics Analysis. Chin. J. Pharm. Analysis38, 67–78. 10.16155/j.0254-1793.2018.01.09
95
SrivastavaS. P.HedayatA. F.KanasakiK.GoodwinJ. E. (2019). microRNA Crosstalk Influences Epithelial-To-Mesenchymal, Endothelial-To-Mesenchymal, and Macrophage-To-Mesenchymal Transitions in the Kidney. Front. Pharmacol.10, 904. 10.3389/fphar.2019.00904
96
SuL. J.ZhangJ. H.GomezH.MuruganR.HongX.XuD.et al (2019). Reactive Oxygen Species-Induced Lipid Peroxidation in Apoptosis, Autophagy, and Ferroptosis. Oxid. Med. Cell. Longev.2019, 5080843. 10.1155/2019/5080843
97
SugiyamaH.KashiharaN.MakinoH.YamasakiY.OtaA. (1996). Apoptosis in Glomerular Sclerosis. Kidney Int.49, 103–111. 10.1038/ki.1996.14
98
TangR.ZhouQ.ShuJ.TangT.AoX.PengW.et al (2009). Effect of Cordyceps Sinensis Extract on Klotho Expression and Apoptosis in Renal Tubular Epithelial Cells Induced by Angiotensin II. Zhong Nan Da Xue Xue Bao Yi Xue Ban.34, 300–307.
99
TangS. C. W.YiuW. H. (2020). Innate Immunity in Diabetic Kidney Disease. Nat. Rev. Nephrol.16, 206–222. 10.1038/s41581-019-0234-4
100
TilgH.MoschenA. R. (2006). Adipocytokines: Mediators Linking Adipose Tissue, Inflammation and Immunity. Nat. Rev. Immunol.6, 772–783. 10.1038/nri1937
101
TomásE.LinY. S.DagherZ.SahaA.LuoZ.IdoY.et al (2002). Hyperglycemia and Insulin Resistance: Possible Mechanisms. Ann. N Y. Acad. Sci.967, 43–51. 10.1111/j.1749-6632.2002.tb04262.x
102
TuliH. S.SandhuS. S.SharmaA. K. (2014). Pharmacological and Therapeutic Potential of Cordyceps with Special Reference to Cordycepin. 3 Biotech.4, 1–12. 10.1007/s13205-013-0121-9
103
TuttleK. R.BakrisG. L.BilousR. W.ChiangJ. L.de BoerI. H.et al (2014). Diabetic Kidney Disease: a Report from an ADA Consensus Conference. Diabetes Care37, 2864–2883. 10.2337/dc14-1296
104
UrnerS.HoF.JhaJ. C.ZieglerD.Jandeleit-DahmK. (2020). NADPH Oxidase Inhibition: Preclinical and Clinical Studies in Diabetic Complications. Antioxid. Redox Signal33, 415–434. 10.1089/ars.2020.8047
105
VonendO.TurnerC. M.ChanC. M.LoeschA.Dell'annaG. C.SraiK. S.et al (2004). Glomerular Expression of the ATP-Sensitive P2X Receptor in Diabetic and Hypertensive Rat Models. Kidney Int.66, 157–166. 10.1111/j.1523-1755.2004.00717.x
106
WadaJ.MakinoH. (2013). Inflammation and the Pathogenesis of Diabetic Nephropathy. Clin. Sci. (Lond)124, 139–152. 10.1042/CS20120198
107
WangC.HouX. X.RuiH. L.LiL. J.ZhaoJ.YangM.et al (2018). Artificially Cultivated Ophiocordyceps Sinensis Alleviates Diabetic Nephropathy and its Podocyte Injury via Inhibiting P2X7R Expression and NLRP3 Inflammasome Activation. J. Diabetes Res.2018, 1390418. 10.1155/2018/1390418
108
WangM.KornsakulkarnJ.SrichomthongK.FengT.LiuJ. K.IsakaM.et al (2019). Antimicrobial Anthraquinones from Cultures of the Ant Pathogenic Fungus Cordyceps Morakotii BCC 56811. J. Antibiot. (Tokyo)72, 141–147. 10.1038/s41429-018-0135-y
109
WangW.ZhangX. N.YinH.LiX. B.HuX. P.LiuH.et al (2013). Effects of Bailing Capsules for Renal Transplant Recipients: a Retrospective Clinical Study. Chin. Med. J. Engl.126, 1895–1899.
110
WangW.QiJ. (2018). Clinical Study of Zhiling Capsule Combined with Telmisartan in Treatment of Early Diabetic Nephropathy. Drugs & Clin.33, 1494–1497.
111
WangY.LiuD.ZhaoH.JiangH.LuoC.WangM.et al (2014). Cordyceps Sinensis Polysaccharide CPS-2 Protects Human Mesangial Cells from PDGF-BB-Induced Proliferation through the PDGF/ERK and TGF-β1/Smad Pathways. Mol. Cell. Endocrinol.382, 979–988. 10.1016/j.mce.2013.11.018
112
WangY.WangY.LiuD.WangW.ZhaoH.WangM.et al (2015). Cordyceps Sinensis Polysaccharide Inhibits PDGF-BB-Induced Inflammation and ROS Production in Human Mesangial Cells. Carbohydr. Polym.125, 135–145. 10.1016/j.carbpol.2015.02.012
113
WeiY.LiM.YuJ. (2019). Research Progress in the Relationship Between Chronic Inflammation and Insulin Resistance. J. Clinical Pathol. Res.39, 640–645. 10.3978/j.issn.2095-6959.2019.03.030
114
Whaley-ConnellA. T.MorrisE. M.RehmerN.YaghoubianJ. C.WeiY.HaydenM. R.et al (2007). Albumin Activation of NAD(P)H Oxidase Activity Is Mediated via Rac1 in Proximal Tubule Cells. Am. J. Nephrol.27, 15–23. 10.1159/000098432
115
WheelerD. C.StefánssonB. V.JongsN.ChertowG. M.GreeneT.HouF. F.et al (2021). Effects of Dapagliflozin on Major Adverse Kidney and Cardiovascular Events in Patients with Diabetic and Non-diabetic Chronic Kidney Disease: a Prespecified Analysis from the DAPA-CKD Trial. Lancet Diabetes & Endocrinol.9, 22–31. 10.1016/s2213-8587(20)30369-7
116
WottonD.MassaguéJ. (2001). Smad Transcriptional Corepressors in TGF Beta Family Signaling. Curr. Top. Microbiol. Immunol.254, 145–164. 10.1007/978-3-662-10595-5_8
117
WuH.WangY.HuF.CaoJ. (2019). Clinical Effects of Jinshuibao Capsules Combined with Irbesartan on Patients with Diabetic Nephropathy. Chin. Tradit. Pat. Med.41, 75–78.
118
WuY.HuN.PanY.ZhouL.ZhouX. (2007). Isolation and Characterization of a Mannoglucan from Edible Cordyceps Sinensis Mycelium. Carbohydr. Res.342, 870–875. 10.1016/j.carres.2007.01.005
119
XiaoL.GeY.SunL.XuX.XieP.ZhanM.et al (2012). Cordycepin Inhibits Albumin-Induced Epithelial-Mesenchymal Transition of Renal Tubular Epithelial Cells by Reducing Reactive Oxygen Species Production. Free Radic. Res.46, 174–183. 10.3109/10715762.2011.647688
120
XingL.GuoH.MengS.ZhuB.FangJ.HuangJ.et al (2021). Klotho Ameliorates Diabetic Nephropathy by Activating Nrf2 Signaling Pathway in Podocytes. Biochem. Biophys. Res. Commun.534, 450–456. 10.1016/j.bbrc.2020.11.061
121
XuB. H.ShengJ.YouY. K.HuangX. R.MaR. C. W.WangQ.et al (2020). Deletion of Smad3 Prevents Renal Fibrosis and Inflammation in Type 2 Diabetic Nephropathy. Metabolism103, 154013. 10.1016/j.metabol.2019.154013
122
YalinW.IshurdO.CuirongS.YuanjiangP. (2005). Structure Analysis and Antitumor Activity of (1-->3)BbetaDdGglucans (Cordyglucans) from the Mycelia of Cordyceps Sinensis. Planta Med.71, 381–384. 10.1055/s-2005-864111
123
YanJ. K.WangW. Q.WuJ. Y. (2014). Recent Advances in Cordyceps Sinensis Polysaccharides: Mycelial Fermentation, Isolation, Structure, and Bioactivities: A Review. J. Funct. Foods6, 33–47. 10.1016/j.jff.2013.11.024
124
YanT.NianT.LiF.HeB.JiaY.BiK.et al (2020). Salidroside From Rhodiola Wallichiana var. Cholaensis Reverses Insulin Resistance and Stimulates the GLP-1 Secretion by Alleviating ROS-Mediated Activation of MAPKs Signaling Pathway and Mitigating Apoptosis. J. Food Biochem.44, e13446. 10.1111/jfbc.13446
125
YangL. Y.HuangW. J.HsiehH. G.LinC. Y. (2003). H1-A Extracted from Cordyceps Sinensis Suppresses the Proliferation of Human Mesangial Cells and Promotes Apoptosis, Probably by Inhibiting the Tyrosine Phosphorylation of Bcl-2 and Bcl-XL. J. Lab. Clin. Med.141, 74–83. 10.1067/mlc.2003.6
126
YangP.ZhaoX. X.ZhangY. W. (2018). Comparison and Review on Specifications of Fermented Cordyceps Sinensis Products. Zhongguo Zhong Yao Za Zhi43, 463–468. 10.19540/j.cnki.cjcmm.20171012.001
127
YinM.ZhangY.LiH. (2019). Advances in Research on Immunoregulation of Macrophages by Plant Polysaccharides. Front. Immunol.10, 145. 10.3389/fimmu.2019.00145
128
YoonS. Y.ParkS. J.ParkY. J. (2018). The Anticancer Properties of Cordycepin and Their Underlying Mechanisms. Int. J. Mol. Sci.19, 3027. 10.3390/ijms19103027
129
YuH. M.WangB. S.HuangS. C.DuhP. D. (2006). Comparison of Protective Effects between Cultured Cordyceps Militaris and Natural Cordyceps Sinensis against Oxidative Damage. J. Agric. Food Chem.54, 3132–3138. 10.1021/jf053111w
130
YueK.YeM.ZhouZ.SunW.LinX. (2013). The Genus Cordyceps: a Chemical and Pharmacological Review. J. Pharm. Pharmacol.65, 474–493. 10.1111/j.2042-7158.2012.01601.x
131
ZatzR.DunnB. R.MeyerT. W.AndersonS.RennkeH. G.BrennerB. M. (1986). Prevention of Diabetic Glomerulopathy by Pharmacological Amelioration of Glomerular Capillary Hypertension. J. Clin. Investig.77, 1925–1930. 10.1172/JCI112521
132
ZhangG.HuangY.BianY.WongJ. H.NgT. B.WangH. (2006). Hypoglycemic Activity of the Fungi Cordyceps Militaris, Cordyceps Sinensis, Tricholoma Mongolicum, and Omphalia Lapidescens in Streptozotocin-Induced Diabetic Rats. Appl. Microbiol. Biotechnol.72, 1152–1156. 10.1007/s00253-006-0411-9
133
ZhangH.LiY.MiJ.ZhangM.WangY.JiangZ.et al (2017). GC-MS Profiling of Volatile Components in Different Fermentation Products of Cordyceps Sinensis Mycelia. Molecules22, 1800. 10.3390/molecules22101800
134
ZhangP.XiaoX.LiY.LinR. (2009). Chemical Analysis of Nucleosides and Alkalines Components in Five Preparations of Fermental Cordyceps. Chin. J. Pharm. Analysis, 889.
135
ZhangW.YangJ.ChenJ.HouY.HanX. (2005a). Immunomodulatory and Antitumour Effects of an Exopolysaccharide Fraction from Cultivated Cordyceps Sinensis (Chinese Caterpillar Fungus) on Tumour-Bearing Mice. Biotechnol. Appl. Biochem.42, 9–15. 10.1042/BA20040183
136
ZhangY.HandyD. E.LoscalzoJ. (2005b). Adenosine-dependent Induction of Glutathione Peroxidase 1 in Human Primary Endothelial Cells and Protection against Oxidative Stress. Circ. Res.96, 831–837. 10.1161/01.RES.0000164401.21929.CF
137
ZhouL.WangS.HaoQ.KangL.KangC.YangJ.et al (2018). Bioaccessibility and Risk Assessment of Heavy Metals, and Analysis of Arsenic Speciation in Cordyceps Sinensis. Chin. Med.13, 40. 10.1186/s13020-018-0196-7
138
ZhuJ. S.HalpernG. M.JonesK. (1998). The Scientific Rediscovery of a Precious Ancient Chinese Herbal Regimen: Cordyceps Sinensis: Part II. J. Altern. Complement. Med.4, 429–457. 10.1089/acm.1998.4.429
139
ZhuL.FuX.ChenX.HanX.DongP. (2017). M2 Macrophages Induce EMT through the TGF-β/Smad2 Signaling Pathway. Cell. Biol. Int.41, 960–968. 10.1002/cbin.10788
Summary
Keywords
Cordyceps sinensis, diabetic kidney disease, hyperglycemia, inflammation, oxidative stress
Citation
Liu W, Gao Y, Zhou Y, Yu F, Li X and Zhang N (2022) Mechanism of Cordyceps sinensis and its Extracts in the Treatment of Diabetic Kidney Disease: A Review. Front. Pharmacol. 13:881835. doi: 10.3389/fphar.2022.881835
Received
23 February 2022
Accepted
27 April 2022
Published
13 May 2022
Volume
13 - 2022
Edited by
Ying-Yong Zhao, Northwest University, China
Reviewed by
Lin-Li Lv, Southeast University, China
Zhao Yu Lu, Guangdong Provincial Academy of Chinese Medical Sciences, China
Updates
Copyright
© 2022 Liu, Gao, Zhou, Yu, Li and Zhang.
This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Ning Zhang, znice3927@126.com
This article was submitted to Ethnopharmacology, a section of the journal Frontiers in Pharmacology
Disclaimer
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.